— Veru Inc. (NASDAQ: VERU) reported Q1 2020 loss of $0.05 per share, vs. $0.02 expected.
— Revenues grew 66% to $10.6 million, vs. $8.7 million expected.
— FC2 US prescription net revenues increased 148% to $6.1 million.
— Gross profit increased 57% to $7.3 million.
— VERU shares were up 3.7% in premarket hours on Wednesday.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Earnings Preview: Accenture (ACN) likely had a strong start to fiscal 2025
For Accenture plc. (NYSE: ACN), 2024 was a fruitful year marked by positive financial performance. The professional service firm effectively navigated a challenging market environment leveraging its agile business model
Signet Jewelers (SIG): Fashion remains a strong point for the jewelery retailer
Shares of Signet Jewelers Limited (NYSE: SIG) were down over 3% on Tuesday. The stock has dropped 12% over the past three months. The company faced challenges in the third
Pfizer (PFE) reaffirms FY24 forecast; provides FY25 guidance
Pharmaceutical company Pfizer Inc. (NYSE: PFE) Tuesday reaffirmed its financial outlook for fiscal 2024 and provided guidance for fiscal 2025. The company said it achieved the goal of $4 bln
